SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)

NEW YORK, March 30, 2022

Shareholders who purchased shares of CABA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/cabaletta-bio-inc-loss-submission-form/?id=25278&from=4

CLASS PERIOD: This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:  (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: April 29, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/cabaletta-bio-inc-loss-submission-form/?id=25278&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CABA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 29, 2022. There is no cost or obligation to you to participate in this case.